Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 7/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | DTYMK | P23919 | 2/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19145537 | 0.87 | LOXL2 (0.47) | LOXL2DTYMKCHRM2CHRM4CHRM1 | |
| SCHEMBL17063253 | 0.83 | FPR2 (0.48) | KRASUSP30KDM4EBACE1 | |
| SCHEMBL19126497 | 0.81 | LOXL2 (0.43) | LOXL2DTYMKCHRM2CHRM4CHRM1 | |
| SCHEMBL29930198 | 0.81 | IDO1 (0.53) | KRASNTSR1IDO1HTR2AHTR2C | |
| SCHEMBL23810852 | 0.81 | NTSR1 (0.51) | KRASNTSR1HTR2AHTR2CHTR7 | |
| SCHEMBL20604745 | 0.79 | KMT2A (0.56) | KRASNTSR1LMNA | |
| SCHEMBL19126538 | 0.77 | GPR119 (0.44) | LOXL2 | |
| SCHEMBL1921265 | 0.77 | MAPT (0.48) | CHRM2CHRM4CHRM1CHRM3LMNA | |
| SCHEMBL4898807 | 0.76 | USP30 (0.50) | USP30KDM4EBACE1 | |
| SCHEMBL6693325 | 0.76 | BACE1 (0.45) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669251-B2 | Quinolin-2-one derivatives | MERCK PATENT GMBH (DE) | 2020-06-02 | — | — | US | disclosed |
| US-20190023685-A1 | QUINOLIN-2-ONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023685-A1 | QUINOLIN-2-ONE DERIVATIVES | KIT, CDK2, CDK1 | KRAS 272/4885LOXL2 3240/4885DTYMK 588/4885 |
| US-10669251-B2 | Quinolin-2-one derivatives | KIT, CDK2, CDK1 | KRAS 272/4885LOXL2 3240/4885DTYMK 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.